FDA clears Roche/Genentech to market Avastin in ovarian cancer
This article was originally published in Scrip
Roche and its US subsidiary Genentech were given the go-ahead by the FDA on 14 November to market Avastin (bevacizumab) plus chemotherapy to treat women with platinum-resistant, recurrent ovarian cancer.
You may also be interested in...
Genentech says it worked closely with the agency to bring the drug to women with earlier-stage disease.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.